Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical need FSHD Canada Foundation to provide up to US$5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD Phase 2 study in FSHD expected to begin in Q4 2026 TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
